{"ticker": {"uuid": "be7ae26e-547b-474e-8f08-4d49fe32c6ae", "symbol": "CLPT", "name": "Clearpoint Neuro Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "EpilepsyGTx Taps ClearPoint Neuro for EPY201 Clinical Trial Delivery", "summary": "EpilepsyGTx has partnered with ClearPoint Neuro to deliver its lead gene therapy candidate, EPY201, for focal refractory epilepsy (FRE) in an upcoming Phase 1/2a clinical trial. EpilepsyGTx will utilize ClearPoint's SmartFlow Cannula and Neuro Navigation system for precise, MRI-g", "url": "https://www.contractpharma.com/breaking-news/epilepsygtx-taps-clearpoint-neuro-for-epy201-clinical-trial-delivery/", "source_name": "Contract Pharma", "published_at": "2026-07-14T13:45:35", "published_display": "14 Jul 2026 13:45", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why I've (Reluctantly) Sold My ClearPoint Neuro Position (NASDAQ:CLPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNb0k0Z1I3TlRxelFUY1pLOGk2dnJlLS1uNkk2SWdaQ3RKT3BBeHBkV2xpMTJFb1pMS2lobDRNbVNDSVdzeDh5NE1JbmNTdzdYb18zUGdSa3J1ZlBIMjBpdVBVSVFNbjFTdWV4NkJfbXo4cGxjSlBtOFptUXRfd3VmVDRyZW9EVUxCNG1BOEJlWFVzWGJxVGdOZA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T13:14:37+00:00", "published_display": "13 Jul 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(CLPT) Risk Channels and Responsive Allocation", "summary": "The article analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) highlighting conflicting sentiment across different time horizons and an oscillation pattern. It identifies an exceptional 101.8:1 risk-reward short setup and outlines three AI-generated trading strategies for various ris", "url": "https://news.stocktradersdaily.com/news_release/11/CLPT_Risk_Channels_and_Responsive_Allocation_071126013002_1783747802.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T01:39:24", "published_display": "11 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Clearpoint Neuro Inc For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for Clearpoint Neuro Inc. (CLPT) for July 6. The company's stock symbol is CLPT, and its price performance is noted as +3.41%. The news brief does not provide further details regarding the content of the Form 4.", "url": "https://ng.investing.com/news/stock-market-news/form-4-clearpoint-neuro-inc-for-6-july-93CH-2587981", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T01:26:00", "published_display": "07 Jul 2026 01:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at ClearPoint Neuro (NASDAQ: CLPT) receives 222-share stock grant", "summary": "ClearPoint Neuro Director Timothy T. Richards was granted 222 shares of Common Stock as compensation for fees under the company's Non-Employee Director Compensation Plan. The shares, valued at $17.84 each, were issued on June 30, 2026, and bring Richards' direct holdings to 87,54", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-4bbae699ee9e.html", "source_name": "Stock Titan", "published_at": "2026-07-07T00:08:46", "published_display": "07 Jul 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] ClearPoint Neuro, Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPdHhGenBoQjlVbV9IUkVtMWt1OWpZYzc4SlNOTHdSQU04WDVIYlBuTFJ3N00tRm9iM3cxN3QtdHpSbFJhdmtCaUZiWHluZUVSY3Q3UUliTXhJNlZmWUE5OHVobmUtSzFnYnJYcDlxeXEyMW43U2FPS1F2dWE3SVp1UWVmWS03UnNHTE5CcV9VSVB1TmtES0dXNTdnWkJaSjJJcjcyakplc1lmXzBQOHk0YWFtYmJWdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLPT - ClearPoint Neuro Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of ClearPoint Neuro Inc (CLPT), including its stock performance, key financial metrics, and volatility indicators. It lists various financial ratios, employee and ownership data, and price performance over different periods. The", "url": "https://finviz.com/stock?t=CLPT&ta=1&p=d&ty=ocv&b=2&r=y1&ov=chain_strike&s=22.5", "source_name": "Finviz", "published_at": "2026-07-04T11:40:03", "published_display": "04 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro outlines growth ambitions in precision neurosurgery", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSkhrYW1VVU5SRGRIeVJFYUNnYnU0cWZCV3d5dWwwc0hpS3Bxc2tMSzl2MWx5aEVOMEJoUWtNbDR4VnJKMExMS2ZEeEZWdkxrTE1ZNnRsVWVLNllRVnVHWTl2bm56TjFGU21WVDltd0hlUDdJeWhwMWZpWjRRU1hXaEJBTnpfbWNlR1NPZVNiWnVVNW5QUGpETS1WQ3BjbGVUdWgyLWhtOEhDMTA3Q0FYOVFhRmZ1SUdrQy1wS2pQUUZnMjhCanc?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-03T13:42:16+00:00", "published_display": "03 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro | 4: Statement of changes in beneficial ownership of securities-Officer BURNETT JOSEPH", "summary": "This document is a statement of changes in beneficial ownership of securities filed by Joseph Burnett, an officer of ClearPoint Neuro. It details changes in his holdings, indicating compliance with disclosure requirements for company insiders.", "url": "https://www.moomoo.com/news/notice/307658645/clearpoint-neuro-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-03T12:39:49", "published_display": "03 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro | 4: Statement of changes in beneficial ownership of securities-Officer STIGALL L. JEREMY", "summary": "This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for ClearPoint Neuro, related to Officer STIGALL L. JEREMY. It indicates a filing concerning alterations in the officer's beneficial ownership of the company's securities.", "url": "https://www.moomoo.com/news/notice/307658650/clearpoint-neuro-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-03T12:13:00", "published_display": "03 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro | 4: Statement of changes in beneficial ownership of securities-Officer D'Alessandro Danilo", "summary": "This document is a Statement of changes in beneficial ownership of securities, specifically Form 4, filed by Officer D'Alessandro Danilo of ClearPoint Neuro. It details changes in his ownership of the company's securities.", "url": "https://www.moomoo.com/news/notice/307658654/clearpoint-neuro-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-02T23:41:24", "published_display": "02 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Clearpoint Neuro Inc For: 2 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Clearpoint Neuro Inc., dated July 2nd. It provides key financial data including market indices, commodity prices, and stock performances for various companies like Clearpoint Neuro (CLPT).", "url": "https://ca.investing.com/news/stock-market-news/form-4-clearpoint-neuro-inc-for-2-july-93CH-4718907", "source_name": "Investing.com Canada", "published_at": "2026-07-02T20:40:05", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CFO acquires 1,085 shares through ESPP", "summary": "ClearPoint Neuro's Chief Financial Officer, Danilo D'Alessandro, acquired 1,085 shares of the company's common stock through an Employee Stock Purchase Plan (ESPP). The shares were purchased at $11.93 each for the period spanning January 1 to June 30, 2026. Following this transac", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-687a5ac7c971.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:06", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CBO adds 1,781 ESPP shares, now holds 110,263", "summary": "ClearPoint Neuro, Inc.'s Chief Business Officer, L. Jeremy Stigall, acquired 1,781 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at $11.93 per share. This transaction, covering the period from January 1, 2026, to June 30, 2026, brings his direct", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-203f8efe17ac.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:05", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CEO acquires 1,361 ESPP shares in Form 4", "summary": "ClearPoint Neuro, Inc. CEO and President Joseph Burnett acquired 1,361 shares of company common stock through an Employee Stock Purchase Plan (ESPP) on June 30, 2026, at $11.93 per share. This purchase, covering the period from January 1 to June 30, 2026, was made at a discount. ", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-83da13adb0a2.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:05", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro CEO Burnett sells $387,600 in company shares By Investing.com", "summary": "ClearPoint Neuro CEO Joseph Burnett sold 20,000 shares of the company's common stock for $387,600 after exercising options. This transaction was part of a pre-arranged trading plan, and Burnett still holds a significant number of shares both directly and indirectly. The sale foll", "url": "https://ng.investing.com/news/stock-market-news/clearpoint-neuro-ceo-burnett-sells-387600-in-company-shares-93CH-2583456", "source_name": "Investing.com Nigeria", "published_at": "2026-07-02T11:10:39", "published_display": "02 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clearpoint Neuro Insider Sold Shares Worth $387,600, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/clearpoint-neuro-insider-sold-shares-081627809.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:16:27+00:00", "published_display": "02 Jul 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro CEO Burnett sells $387,600 in company shares", "summary": "Joseph Burnett, CEO and President of ClearPoint Neuro, Inc., sold 20,000 shares of the company\u2019s common stock for $387,600 after exercising options. The transaction was pre-arranged, and Burnett still holds a significant number of shares both directly and indirectly. This sale fo", "url": "https://www.investing.com/news/insider-trading-news/clearpoint-neuro-ceo-burnett-sells-387600-in-company-shares-93CH-4771973", "source_name": "Investing.com", "published_at": "2026-07-02T06:39:11", "published_display": "02 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article provides financial information for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its price-to-book forward metric. It details where to find financial data, news, and other market-related information for the company on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T01:10:19", "published_display": "02 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Clearpoint Neuro Inc For: 1 July By Investing.com", "summary": "This article announces the filing of Form 4 for Clearpoint Neuro Inc. on July 1st. It also includes general market data, popular news headlines, and an image indicating its source is Reuters.", "url": "https://ca.investing.com/news/stock-market-news/form-4-clearpoint-neuro-inc-for-1-july-93CH-4717326", "source_name": "Investing.com Canada", "published_at": "2026-07-01T22:39:11", "published_display": "01 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CEO exercises options and sells 20,000 shares under 10b5-1 plan", "summary": "ClearPoint Neuro (CLPT) CEO Joseph Burnett exercised stock options to acquire 20,000 shares at $2.50 each and subsequently sold 20,000 shares at a weighted average price of $19.38. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 11,", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-8ce35af01ca4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:39:11", "published_display": "01 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article provides financial data for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its \"Price to sales forward\" metric. It appears to be a stub or a data point from a financial platform like TradingView, indicating a value change for this specific financial r", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T17:10:03", "published_display": "01 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article provides financial information for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its forward price-to-earnings ratio. It presents a table showing the period, value, change, and percentage change for this metric, noting that the data is \"Made by human", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:10:06", "published_display": "01 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director sale notice, CLPT (NASDAQ: CLPT) \u2014 20,000 shares via option exercise", "summary": "This article reports that a director of ClearPoint Neuro, Inc. (NASDAQ: CLPT) has filed a Form 144 for the proposed sale of 20,000 shares of common stock through the exercise of stock options on June 29, 2026. The filing also details prior 10b5-1 sales by Joseph M. Burnett and th", "url": "https://www.stocktitan.net/sec-filings/CLPT/144-clear-point-neuro-inc-sec-filing-332c8972bb4b.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:43:10", "published_display": "29 Jun 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(CLPT) Movement as an Input in Quant Signal Sets", "summary": "This article provides an in-depth quantitative analysis of Clearpoint Neuro, Inc. (NASDAQ: CLPT), highlighting strong near- and mid-term sentiment despite a weak long-term outlook. It details three AI-generated institutional trading strategies\u2014Position Trading, Momentum Breakout,", "url": "https://news.stocktradersdaily.com/news_release/14/CLPT_Movement_as_an_Input_in_Quant_Signal_Sets_063026122202_1782793322.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T00:42:05", "published_display": "29 Jun 2026 00:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article from TradingView provides a financial metric, the enterprise value to EBIT forward, for ClearPoint Neuro Inc. (NASDAQ: CLPT). It indicates that the company's market is currently closed with no trades. The piece highlights a specific financial performance indicator fo", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:09:31", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article provides financial information for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial data snippet from TradingView, indicating that the stock market for CLPT is currently clos", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:41:04", "published_display": "28 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro, Inc. Actuals & Estimates (NASDAQ:CLPT)", "summary": "This article provides an overview of ClearPoint Neuro Inc. (NASDAQ: CLPT) stock performance, forecasts, and financial data. It covers historical price movements, analyst price targets, upcoming earnings dates, and recent financial results including revenue, net income, and EBITDA", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:51", "published_display": "26 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLPT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for ClearPoint Neuro Inc. (CLPT) stock, including analyst price targets and predictions for 2027. It details the company's financial performance, stock volatility, market capitalization, earnings, revenue, and historical price data. The forecast in", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:39", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Announces Target Price $30", "summary": "Lake Street has reiterated its Buy rating for ClearPoint Neuro (CLPT.US) and set a price target of $30. This indicates a positive outlook on the company's stock performance from the analyst firm.", "url": "https://www.moomoo.com/news/post/71902162/lake-street-maintains-clearpoint-neuro-clptus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-23T15:40:06", "published_display": "23 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clearpoint Neuro Inc (CLPT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Clearpoint Neuro Inc (CLPT) by TradingKey. It details the company's current valuation score of 9.41, ranking it 16th in the Healthcare Equipment & Supplies industry, and its P/E ratio. The analysis also highlights that relevant data f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clpt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T07:10:43", "published_display": "23 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), uniQure (QURE)", "summary": "Analysts are showing bullish sentiment towards two healthcare stocks, ClearPoint Neuro (CLPT) and uniQure (QURE). Stifel Nicolaus maintained a Buy rating on ClearPoint Neuro with a $25.00 price target, while the consensus price target is $27.50, suggesting a significant upside. F", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2593955/analysts-are-bullish-on-top-healthcare-stocks-clearpoint-neuro-clpt-uniqure-qure/", "source_name": "The Globe and Mail", "published_at": "2026-06-23T02:11:10", "published_display": "23 Jun 2026 02:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CEO sells 61,843 shares after exercising options", "summary": "ClearPoint Neuro (CLPT) CEO and President Joseph Burnett executed an exercise-and-sell transaction, exercising 60,000 stock options at $2.50 per share and selling 60,000 directly held shares at an average of $17.79. Additionally, a trust managed by Burnett sold 1,843 shares at $1", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-5ff9459dc0ee.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:10", "published_display": "22 Jun 2026 20:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOUkJ6VXItS3pyOF9XQzdSTV93Zk8wblgzcXZISDVwdlpzQklna2Q0dzFGX0s1eE5DOTRCTEdoRGUtVko3akdGNjZYamR1UDVEYmUzZ1RsLUMtMW0xdWVLT1l2ZEhwSjFwR1Nvc1piU1ZGQjhraE95S3FjcHM3SmZCQmZzN3NIXzAwTXRsN2ZtSlFxSTVXNXN1T2NQNmI?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case (NASDAQ:CLPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNS1BkaGhBLXN5SER6c0F5TFFVZ2JnWWg0TXROLWctNkFFcm9kTzR4S0FPQmlyNlBNRVlJTU4tZTY2Z0lDa0tQWEJGOURmU3Q4SWgyd25ZcXdvVHBsN04zZ1hJMnY1TFBzZE5meTJ6OUVWeWMtTlZQcl9jam1tcU9CdU1GU3plU0x6d0VxWlhXblM4U3cxRjloQjhTa0JUcHNlczh1UQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value", "summary": "", "url": "https://finance.yahoo.com/m/58f74ac7-cb48-33cf-ada1-b642dcf39b48/clearpoint-neuro-shares-jump.html", "source_name": "InvestorsHub", "published_at": "2026-06-17T12:56:52+00:00", "published_display": "17 Jun 2026 12:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro stock surges on peer\u2019s FDA approval plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPWGl0bFlYYjR3M1RNX2ZlTjF4YkJQYVZiZ2w2QVhVdjdNQ0FjQTYtWmJYNk1EYm1QRVJYOG1aTUIycEtPZF9xaHVNLUV2SzQ2N0k1TTFOTFBwSHpTMjVPNG5QTGhBYkI3Nk9WaTdvWElaa2RhdGl4aXVPWm1URDI3c09PM3RYbENCa1FXaGFFZDZJNFluSjRpSXBUcTZMRG5LdnJDX1YyVUVuZUhjVzdtNmQ1QVQ4T3FiY0E?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) Sees Significant Pre-Market Gains Following Partner Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPUkQ0WWlNNzhYVS1NTE42bEtha21aMkVoOFFOQnQyTDhFcko1WGJpNkZXWTRjVEdkZnluMzNYZHJibkpvRXhMNENUczYzRUVYQlU1TmVzczY2c0UyU3NYVEkwb3h5YlF1elBPN0xiNUgxc2NteGs2c1dVa2hZUHNhYmE0aGlMeERnMTRVMVdmSWFuNUs1TkwzU3kzdG9MZHRCZkpXNmpvMGM3OGIyVFdBTDV2QmFTdnFYTndZa25ETVVBZFRtRzF2bUFXTHJFNWtnUExPRXpXbjgzb1JnbUpHbjFn?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[144] ClearPoint Neuro, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQjAydzVhRFEySnJQYnBNa05yNno2WDBpSDZZTlQ3azJZb1JqQXZMLUlBU0ZndHZ5bXhxWDk5WkJOZ0drVTF5eklhZVQxV1hXY3drSnBQajFtWUViamJab0dqWWZYTkJxeGoxeE54UFYybW1YWUJaTHUxdW4wZUFkVmRuSGVxaTBlR1BVNWNrTG9JMTlFSVlCRk53VGZGcXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/clearpoint-neuro-enters-10-focused-203000199.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-27T20:30:00+00:00", "published_display": "27 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The ClearPoint Neuro (CLPT) Narrative Is Shifting On Partnerships Valuation And FDA Risks", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/clearpoint-neuro-clpt-narrative-shifting-011803069.html", "source_name": "Simply Wall St.", "published_at": "2026-05-27T01:18:03+00:00", "published_display": "27 May 2026 01:18", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ClearPoint Neuro Inc (CLPT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/clearpoint-neuro-inc-clpt-q1-010143836.html", "source_name": "GuruFocus.com", "published_at": "2026-05-19T01:01:43+00:00", "published_display": "19 May 2026 01:01", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/590b7ca9-2f13-35e0-a5cd-f4257cb7f0c5/clearpoint-neuro-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-13T22:05:25+00:00", "published_display": "13 May 2026 22:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Secures CE Marking for Surgical Drill System", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/clearpoint-neuro-secures-ce-marking-214804833.html", "source_name": "MT Newswires", "published_at": "2026-05-13T21:48:04+00:00", "published_display": "13 May 2026 21:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Q1 2026 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/news/clearpoint-neuro-q1-2026-earnings-213859347.html", "source_name": "Benzinga", "published_at": "2026-05-13T21:38:59+00:00", "published_display": "13 May 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compared to Estimates, ClearPoint Neuro (CLPT) Q1 Earnings: A Look at Key Metrics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTi01NHhRdm0tQVVYN3BmVFQwdHBOTWk3TEhuNHE5eVFVakozMVl4X0JNbjVPRFY1ZmZuNDd0Y2pYcEFlTUFiV3F3aVdPNDFjaEpjLVJLUG9kZVZtdEFtcmFLelE4Wm1CSDFlaElhR0NYQXlJY1RsekFFWWtvM0dia21LTWdsRzFRZ0k2LWZzb3BveDVfNGpDMDVYUXphcDJ2VWVIbmxlVnQ?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOSVd0b19VdGtYRzZrRzBZZFNXWUhKcVFJaTU4cWZ6bXRxMy1NTTJQVTdTV2g3anpBR1lIbENGRV9GS0NYcXlDdzZqcEJJSWVBSkhSYm83ak5QdFB1UG9uNEdWMTQtcWQtMTVyNWZ6N3c5SFE0dFo2S2pjcVo0enlEWlR2Xy1yTWxLNTZFcmVlRFF5QU5iVWpNc29PMkVQb2M?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro schedules May 13 earnings call after market close", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQVHREZUF4SUN1c0MyZzlLd3d1dmlQWW1VMjktZ1hmbjFXRUxWOVp1QjQzT3R6bWJaZFB0VjJ1T01wYWVpUnkteXdOcU4xRDNKZ2NOQ2xEWU51bzZVUHFmcmYzcjA3VUd0MUVtRjVZamlsMll2dnJvdlZYVVlmTlZxNjhBZWdJY2VpbVNBT1NlTGI0cVRFMmZGVmpxTWpVU2N3cWs5aHA3d0NUSEVhcW5SbXFkOFFRay1qeEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ClearPoint's brain surgery drill gets FDA clearance, first clinical use", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZTA1RXktMTJCRnIxLWp5ZlRXTUFXdUJqbTNsZFdDN2VSQnJLSV8xOG4zc0pjZXBXOFU3WGl2UWd2X1VHbGdxcUw0cVA4MmN6SjhDNEQxREh6RmZ3MmxTbWVQeHpLY19aaXRrbGwtN0FXRWloUjB2RlBDcW8zaTJqTkxVNFR3NmdncVN3aVFTRXVhVWNqbEwwTDJoak52bDV2cExvblpZM2QtMEduZXpiWFpUelBOTFRHUi1lTU1qd28?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canada clears ClearPoint brain navigation system for clinical trial sites", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcExGeWt6cHpDVVJPUVQ4VWFVNXNnRnVwZFVQRkVtWDhFTnZRUHc5a2NsQU9zSzQ2Z3pRQzFqOVVReXI4V0NTc0ctVlBVR2lsaWNWbjRQcExGSXEwcW56WXdZU1RNREp3ZmRlaVhBaGRxVktBT1hkcEpTc25HQW1BUXcxaXEzWkdHSWpHcEVLeGZua3RDblRLZUoxMEVIUnBGSHpudmdQUElXclJLWFFMNmFHTzhNQ3podVB3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why The ClearPoint Neuro (CLPT) Investment Story Is Shifting On Regulatory And Partnership Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNENYcTJrWkFrbzQzU0lkWnFFWDc0alpsSkxnSlBqQkY3M0pIVVg2RWVSaDAwTm9fdUpTam9UWUdLNEZjTmdMWTd4N1QxX29hcUlrdGdkV1IzUUVzamVaOUNnRTdZWDFGb3JjbjAtRUppblRqenBJSk9GYko4dFhyOGl5NlcxX1pXbzNKV2JSelU0aVRmQU12MncxSVEzUFBPX0RvMVVoTFM?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why The ClearPoint Neuro (CLPT) Story Is Shifting After New Partner And FDA Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPVjRmX1l0UFFUV011QmVqb0FHNmZ3cmF2ZWkyNFBYOWdCQTV5TVhWZ1RWMFVOU2Z6T2dRN0k0Uk5NcTEwdE91MzdGOUNva0xIUmxxc05Xc3BmcFYxU1Vma3hfQ0JrSC1xM29QNEFBaU5pVGY1NFV0ZmNxc0E1bEdTdUszWlU0RTk1dnJEa21SeUlwSU1PbjJ1MnE4OGJPcXBCUmc?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro FY 2025 Revenue Growth Reinforces Bullish Narratives Despite Persistent EPS Losses", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQOUs1UFlGVlV6RS1jSEpxWnFqd3pkZUZIRVJFRzZLbk82TlhQOF9wdnkxczRQY1cxQkh5b0RTNDdKbE83NmJudFhMRHJqQnd6aEs3TzU2OU1YLVFwVU9INXlZVkZGeVVqSlBWZ0JQQzFSX1RBSlZaY3hBNFZMNmVqWklneVktYmtTOHp6T0tzZkYwbnItWHdtakdscDUxQ0syeE5DQlZKM0dXM3dPSHMxeGpoRTBhX0dCMnEzT2dMSEdaTVZoMkZyX2x0UUotdVZRUmRB0gHYAUFVX3lxTFBhZkNXMnJDdUtvQ1d4cnNMZ3d0OVdURDNoX2tocFNiTUlwOVlJZUd1dkNHTFQ3SXlEYXI4RVRaNjlXcGx4Y053Z3BIcmxHeW5HbEdjVTB2dHZ1a2hGSnN5ZEJrRVNEa1JmWU9OQjAzMXhQbnI0V0JpVUNnVy1SRGxoUS0wV20xUDBUQXNGeUJnT1JTMEV6a0pIcGdoejQzbmIxcXkteW1sR1Z6MEtuTGVUMFRQazV1VE8yblZxbWMxcndDRjlfNUphUW9XSVFlUTB0OVMwT0xSdw?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "EpilepsyGTx Taps ClearPoint Neuro for EPY201 Clinical Trial Delivery", "summary": "EpilepsyGTx has partnered with ClearPoint Neuro to deliver its lead gene therapy candidate, EPY201, for focal refractory epilepsy (FRE) in an upcoming Phase 1/2a clinical trial. EpilepsyGTx will utilize ClearPoint's SmartFlow Cannula and Neuro Navigation system for precise, MRI-g", "url": "https://www.contractpharma.com/breaking-news/epilepsygtx-taps-clearpoint-neuro-for-epy201-clinical-trial-delivery/", "source_name": "Contract Pharma", "published_at": "2026-07-14T13:45:35", "published_display": "14 Jul 2026 13:45", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why I've (Reluctantly) Sold My ClearPoint Neuro Position (NASDAQ:CLPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNb0k0Z1I3TlRxelFUY1pLOGk2dnJlLS1uNkk2SWdaQ3RKT3BBeHBkV2xpMTJFb1pMS2lobDRNbVNDSVdzeDh5NE1JbmNTdzdYb18zUGdSa3J1ZlBIMjBpdVBVSVFNbjFTdWV4NkJfbXo4cGxjSlBtOFptUXRfd3VmVDRyZW9EVUxCNG1BOEJlWFVzWGJxVGdOZA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T13:14:37+00:00", "published_display": "13 Jul 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(CLPT) Risk Channels and Responsive Allocation", "summary": "The article analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) highlighting conflicting sentiment across different time horizons and an oscillation pattern. It identifies an exceptional 101.8:1 risk-reward short setup and outlines three AI-generated trading strategies for various ris", "url": "https://news.stocktradersdaily.com/news_release/11/CLPT_Risk_Channels_and_Responsive_Allocation_071126013002_1783747802.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T01:39:24", "published_display": "11 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Clearpoint Neuro Inc For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for Clearpoint Neuro Inc. (CLPT) for July 6. The company's stock symbol is CLPT, and its price performance is noted as +3.41%. The news brief does not provide further details regarding the content of the Form 4.", "url": "https://ng.investing.com/news/stock-market-news/form-4-clearpoint-neuro-inc-for-6-july-93CH-2587981", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T01:26:00", "published_display": "07 Jul 2026 01:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at ClearPoint Neuro (NASDAQ: CLPT) receives 222-share stock grant", "summary": "ClearPoint Neuro Director Timothy T. Richards was granted 222 shares of Common Stock as compensation for fees under the company's Non-Employee Director Compensation Plan. The shares, valued at $17.84 each, were issued on June 30, 2026, and bring Richards' direct holdings to 87,54", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-4bbae699ee9e.html", "source_name": "Stock Titan", "published_at": "2026-07-07T00:08:46", "published_display": "07 Jul 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] ClearPoint Neuro, Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPdHhGenBoQjlVbV9IUkVtMWt1OWpZYzc4SlNOTHdSQU04WDVIYlBuTFJ3N00tRm9iM3cxN3QtdHpSbFJhdmtCaUZiWHluZUVSY3Q3UUliTXhJNlZmWUE5OHVobmUtSzFnYnJYcDlxeXEyMW43U2FPS1F2dWE3SVp1UWVmWS03UnNHTE5CcV9VSVB1TmtES0dXNTdnWkJaSjJJcjcyakplc1lmXzBQOHk0YWFtYmJWdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLPT - ClearPoint Neuro Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of ClearPoint Neuro Inc (CLPT), including its stock performance, key financial metrics, and volatility indicators. It lists various financial ratios, employee and ownership data, and price performance over different periods. The", "url": "https://finviz.com/stock?t=CLPT&ta=1&p=d&ty=ocv&b=2&r=y1&ov=chain_strike&s=22.5", "source_name": "Finviz", "published_at": "2026-07-04T11:40:03", "published_display": "04 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro outlines growth ambitions in precision neurosurgery", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSkhrYW1VVU5SRGRIeVJFYUNnYnU0cWZCV3d5dWwwc0hpS3Bxc2tMSzl2MWx5aEVOMEJoUWtNbDR4VnJKMExMS2ZEeEZWdkxrTE1ZNnRsVWVLNllRVnVHWTl2bm56TjFGU21WVDltd0hlUDdJeWhwMWZpWjRRU1hXaEJBTnpfbWNlR1NPZVNiWnVVNW5QUGpETS1WQ3BjbGVUdWgyLWhtOEhDMTA3Q0FYOVFhRmZ1SUdrQy1wS2pQUUZnMjhCanc?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-03T13:42:16+00:00", "published_display": "03 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro | 4: Statement of changes in beneficial ownership of securities-Officer BURNETT JOSEPH", "summary": "This document is a statement of changes in beneficial ownership of securities filed by Joseph Burnett, an officer of ClearPoint Neuro. It details changes in his holdings, indicating compliance with disclosure requirements for company insiders.", "url": "https://www.moomoo.com/news/notice/307658645/clearpoint-neuro-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-03T12:39:49", "published_display": "03 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro | 4: Statement of changes in beneficial ownership of securities-Officer STIGALL L. JEREMY", "summary": "This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for ClearPoint Neuro, related to Officer STIGALL L. JEREMY. It indicates a filing concerning alterations in the officer's beneficial ownership of the company's securities.", "url": "https://www.moomoo.com/news/notice/307658650/clearpoint-neuro-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-03T12:13:00", "published_display": "03 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro | 4: Statement of changes in beneficial ownership of securities-Officer D'Alessandro Danilo", "summary": "This document is a Statement of changes in beneficial ownership of securities, specifically Form 4, filed by Officer D'Alessandro Danilo of ClearPoint Neuro. It details changes in his ownership of the company's securities.", "url": "https://www.moomoo.com/news/notice/307658654/clearpoint-neuro-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-02T23:41:24", "published_display": "02 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Clearpoint Neuro Inc For: 2 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Clearpoint Neuro Inc., dated July 2nd. It provides key financial data including market indices, commodity prices, and stock performances for various companies like Clearpoint Neuro (CLPT).", "url": "https://ca.investing.com/news/stock-market-news/form-4-clearpoint-neuro-inc-for-2-july-93CH-4718907", "source_name": "Investing.com Canada", "published_at": "2026-07-02T20:40:05", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CFO acquires 1,085 shares through ESPP", "summary": "ClearPoint Neuro's Chief Financial Officer, Danilo D'Alessandro, acquired 1,085 shares of the company's common stock through an Employee Stock Purchase Plan (ESPP). The shares were purchased at $11.93 each for the period spanning January 1 to June 30, 2026. Following this transac", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-687a5ac7c971.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:06", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CBO adds 1,781 ESPP shares, now holds 110,263", "summary": "ClearPoint Neuro, Inc.'s Chief Business Officer, L. Jeremy Stigall, acquired 1,781 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at $11.93 per share. This transaction, covering the period from January 1, 2026, to June 30, 2026, brings his direct", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-203f8efe17ac.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:05", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CEO acquires 1,361 ESPP shares in Form 4", "summary": "ClearPoint Neuro, Inc. CEO and President Joseph Burnett acquired 1,361 shares of company common stock through an Employee Stock Purchase Plan (ESPP) on June 30, 2026, at $11.93 per share. This purchase, covering the period from January 1 to June 30, 2026, was made at a discount. ", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-83da13adb0a2.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:05", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro CEO Burnett sells $387,600 in company shares By Investing.com", "summary": "ClearPoint Neuro CEO Joseph Burnett sold 20,000 shares of the company's common stock for $387,600 after exercising options. This transaction was part of a pre-arranged trading plan, and Burnett still holds a significant number of shares both directly and indirectly. The sale foll", "url": "https://ng.investing.com/news/stock-market-news/clearpoint-neuro-ceo-burnett-sells-387600-in-company-shares-93CH-2583456", "source_name": "Investing.com Nigeria", "published_at": "2026-07-02T11:10:39", "published_display": "02 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clearpoint Neuro Insider Sold Shares Worth $387,600, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/clearpoint-neuro-insider-sold-shares-081627809.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:16:27+00:00", "published_display": "02 Jul 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro CEO Burnett sells $387,600 in company shares", "summary": "Joseph Burnett, CEO and President of ClearPoint Neuro, Inc., sold 20,000 shares of the company\u2019s common stock for $387,600 after exercising options. The transaction was pre-arranged, and Burnett still holds a significant number of shares both directly and indirectly. This sale fo", "url": "https://www.investing.com/news/insider-trading-news/clearpoint-neuro-ceo-burnett-sells-387600-in-company-shares-93CH-4771973", "source_name": "Investing.com", "published_at": "2026-07-02T06:39:11", "published_display": "02 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article provides financial information for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its price-to-book forward metric. It details where to find financial data, news, and other market-related information for the company on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T01:10:19", "published_display": "02 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Clearpoint Neuro Inc For: 1 July By Investing.com", "summary": "This article announces the filing of Form 4 for Clearpoint Neuro Inc. on July 1st. It also includes general market data, popular news headlines, and an image indicating its source is Reuters.", "url": "https://ca.investing.com/news/stock-market-news/form-4-clearpoint-neuro-inc-for-1-july-93CH-4717326", "source_name": "Investing.com Canada", "published_at": "2026-07-01T22:39:11", "published_display": "01 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CEO exercises options and sells 20,000 shares under 10b5-1 plan", "summary": "ClearPoint Neuro (CLPT) CEO Joseph Burnett exercised stock options to acquire 20,000 shares at $2.50 each and subsequently sold 20,000 shares at a weighted average price of $19.38. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 11,", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-8ce35af01ca4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:39:11", "published_display": "01 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article provides financial data for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its \"Price to sales forward\" metric. It appears to be a stub or a data point from a financial platform like TradingView, indicating a value change for this specific financial r", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T17:10:03", "published_display": "01 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article provides financial information for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its forward price-to-earnings ratio. It presents a table showing the period, value, change, and percentage change for this metric, noting that the data is \"Made by human", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:10:06", "published_display": "01 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director sale notice, CLPT (NASDAQ: CLPT) \u2014 20,000 shares via option exercise", "summary": "This article reports that a director of ClearPoint Neuro, Inc. (NASDAQ: CLPT) has filed a Form 144 for the proposed sale of 20,000 shares of common stock through the exercise of stock options on June 29, 2026. The filing also details prior 10b5-1 sales by Joseph M. Burnett and th", "url": "https://www.stocktitan.net/sec-filings/CLPT/144-clear-point-neuro-inc-sec-filing-332c8972bb4b.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:43:10", "published_display": "29 Jun 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(CLPT) Movement as an Input in Quant Signal Sets", "summary": "This article provides an in-depth quantitative analysis of Clearpoint Neuro, Inc. (NASDAQ: CLPT), highlighting strong near- and mid-term sentiment despite a weak long-term outlook. It details three AI-generated institutional trading strategies\u2014Position Trading, Momentum Breakout,", "url": "https://news.stocktradersdaily.com/news_release/14/CLPT_Movement_as_an_Input_in_Quant_Signal_Sets_063026122202_1782793322.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T00:42:05", "published_display": "29 Jun 2026 00:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article from TradingView provides a financial metric, the enterprise value to EBIT forward, for ClearPoint Neuro Inc. (NASDAQ: CLPT). It indicates that the company's market is currently closed with no trades. The piece highlights a specific financial performance indicator fo", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:09:31", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ClearPoint Neuro Inc. \u2013 NASDAQ:CLPT", "summary": "This article provides financial information for ClearPoint Neuro Inc. (NASDAQ: CLPT), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial data snippet from TradingView, indicating that the stock market for CLPT is currently clos", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:41:04", "published_display": "28 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro, Inc. Actuals & Estimates (NASDAQ:CLPT)", "summary": "This article provides an overview of ClearPoint Neuro Inc. (NASDAQ: CLPT) stock performance, forecasts, and financial data. It covers historical price movements, analyst price targets, upcoming earnings dates, and recent financial results including revenue, net income, and EBITDA", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:51", "published_display": "26 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLPT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for ClearPoint Neuro Inc. (CLPT) stock, including analyst price targets and predictions for 2027. It details the company's financial performance, stock volatility, market capitalization, earnings, revenue, and historical price data. The forecast in", "url": "https://www.tradingview.com/symbols/NASDAQ-CLPT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:39", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Announces Target Price $30", "summary": "Lake Street has reiterated its Buy rating for ClearPoint Neuro (CLPT.US) and set a price target of $30. This indicates a positive outlook on the company's stock performance from the analyst firm.", "url": "https://www.moomoo.com/news/post/71902162/lake-street-maintains-clearpoint-neuro-clptus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-23T15:40:06", "published_display": "23 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clearpoint Neuro Inc (CLPT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Clearpoint Neuro Inc (CLPT) by TradingKey. It details the company's current valuation score of 9.41, ranking it 16th in the Healthcare Equipment & Supplies industry, and its P/E ratio. The analysis also highlights that relevant data f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clpt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T07:10:43", "published_display": "23 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), uniQure (QURE)", "summary": "Analysts are showing bullish sentiment towards two healthcare stocks, ClearPoint Neuro (CLPT) and uniQure (QURE). Stifel Nicolaus maintained a Buy rating on ClearPoint Neuro with a $25.00 price target, while the consensus price target is $27.50, suggesting a significant upside. F", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2593955/analysts-are-bullish-on-top-healthcare-stocks-clearpoint-neuro-clpt-uniqure-qure/", "source_name": "The Globe and Mail", "published_at": "2026-06-23T02:11:10", "published_display": "23 Jun 2026 02:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) CEO sells 61,843 shares after exercising options", "summary": "ClearPoint Neuro (CLPT) CEO and President Joseph Burnett executed an exercise-and-sell transaction, exercising 60,000 stock options at $2.50 per share and selling 60,000 directly held shares at an average of $17.79. Additionally, a trust managed by Burnett sold 1,843 shares at $1", "url": "https://www.stocktitan.net/sec-filings/CLPT/form-4-clear-point-neuro-inc-insider-trading-activity-5ff9459dc0ee.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:10", "published_display": "22 Jun 2026 20:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOUkJ6VXItS3pyOF9XQzdSTV93Zk8wblgzcXZISDVwdlpzQklna2Q0dzFGX0s1eE5DOTRCTEdoRGUtVko3akdGNjZYamR1UDVEYmUzZ1RsLUMtMW0xdWVLT1l2ZEhwSjFwR1Nvc1piU1ZGQjhraE95S3FjcHM3SmZCQmZzN3NIXzAwTXRsN2ZtSlFxSTVXNXN1T2NQNmI?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case (NASDAQ:CLPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNS1BkaGhBLXN5SER6c0F5TFFVZ2JnWWg0TXROLWctNkFFcm9kTzR4S0FPQmlyNlBNRVlJTU4tZTY2Z0lDa0tQWEJGOURmU3Q4SWgyd25ZcXdvVHBsN04zZ1hJMnY1TFBzZE5meTJ6OUVWeWMtTlZQcl9jam1tcU9CdU1GU3plU0x6d0VxWlhXblM4U3cxRjloQjhTa0JUcHNlczh1UQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value", "summary": "", "url": "https://finance.yahoo.com/m/58f74ac7-cb48-33cf-ada1-b642dcf39b48/clearpoint-neuro-shares-jump.html", "source_name": "InvestorsHub", "published_at": "2026-06-17T12:56:52+00:00", "published_display": "17 Jun 2026 12:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro stock surges on peer\u2019s FDA approval plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPWGl0bFlYYjR3M1RNX2ZlTjF4YkJQYVZiZ2w2QVhVdjdNQ0FjQTYtWmJYNk1EYm1QRVJYOG1aTUIycEtPZF9xaHVNLUV2SzQ2N0k1TTFOTFBwSHpTMjVPNG5QTGhBYkI3Nk9WaTdvWElaa2RhdGl4aXVPWm1URDI3c09PM3RYbENCa1FXaGFFZDZJNFluSjRpSXBUcTZMRG5LdnJDX1YyVUVuZUhjVzdtNmQ1QVQ4T3FiY0E?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro (CLPT) Sees Significant Pre-Market Gains Following Partner Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPUkQ0WWlNNzhYVS1NTE42bEtha21aMkVoOFFOQnQyTDhFcko1WGJpNkZXWTRjVEdkZnluMzNYZHJibkpvRXhMNENUczYzRUVYQlU1TmVzczY2c0UyU3NYVEkwb3h5YlF1elBPN0xiNUgxc2NteGs2c1dVa2hZUHNhYmE0aGlMeERnMTRVMVdmSWFuNUs1TkwzU3kzdG9MZHRCZkpXNmpvMGM3OGIyVFdBTDV2QmFTdnFYTndZa25ETVVBZFRtRzF2bUFXTHJFNWtnUExPRXpXbjgzb1JnbUpHbjFn?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ClearPoint Neuro, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQjAydzVhRFEySnJQYnBNa05yNno2WDBpSDZZTlQ3azJZb1JqQXZMLUlBU0ZndHZ5bXhxWDk5WkJOZ0drVTF5eklhZVQxV1hXY3drSnBQajFtWUViamJab0dqWWZYTkJxeGoxeE54UFYybW1YWUJaTHUxdW4wZUFkVmRuSGVxaTBlR1BVNWNrTG9JMTlFSVlCRk53VGZGcXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/clearpoint-neuro-enters-10-focused-203000199.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-27T20:30:00+00:00", "published_display": "27 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The ClearPoint Neuro (CLPT) Narrative Is Shifting On Partnerships Valuation And FDA Risks", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/clearpoint-neuro-clpt-narrative-shifting-011803069.html", "source_name": "Simply Wall St.", "published_at": "2026-05-27T01:18:03+00:00", "published_display": "27 May 2026 01:18", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Inc (CLPT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/clearpoint-neuro-inc-clpt-q1-010143836.html", "source_name": "GuruFocus.com", "published_at": "2026-05-19T01:01:43+00:00", "published_display": "19 May 2026 01:01", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/590b7ca9-2f13-35e0-a5cd-f4257cb7f0c5/clearpoint-neuro-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-13T22:05:25+00:00", "published_display": "13 May 2026 22:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Secures CE Marking for Surgical Drill System", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/clearpoint-neuro-secures-ce-marking-214804833.html", "source_name": "MT Newswires", "published_at": "2026-05-13T21:48:04+00:00", "published_display": "13 May 2026 21:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro Q1 2026 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/news/clearpoint-neuro-q1-2026-earnings-213859347.html", "source_name": "Benzinga", "published_at": "2026-05-13T21:38:59+00:00", "published_display": "13 May 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compared to Estimates, ClearPoint Neuro (CLPT) Q1 Earnings: A Look at Key Metrics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTi01NHhRdm0tQVVYN3BmVFQwdHBOTWk3TEhuNHE5eVFVakozMVl4X0JNbjVPRFY1ZmZuNDd0Y2pYcEFlTUFiV3F3aVdPNDFjaEpjLVJLUG9kZVZtdEFtcmFLelE4Wm1CSDFlaElhR0NYQXlJY1RsekFFWWtvM0dia21LTWdsRzFRZ0k2LWZzb3BveDVfNGpDMDVYUXphcDJ2VWVIbmxlVnQ?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOSVd0b19VdGtYRzZrRzBZZFNXWUhKcVFJaTU4cWZ6bXRxMy1NTTJQVTdTV2g3anpBR1lIbENGRV9GS0NYcXlDdzZqcEJJSWVBSkhSYm83ak5QdFB1UG9uNEdWMTQtcWQtMTVyNWZ6N3c5SFE0dFo2S2pjcVo0enlEWlR2Xy1yTWxLNTZFcmVlRFF5QU5iVWpNc29PMkVQb2M?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro schedules May 13 earnings call after market close", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQVHREZUF4SUN1c0MyZzlLd3d1dmlQWW1VMjktZ1hmbjFXRUxWOVp1QjQzT3R6bWJaZFB0VjJ1T01wYWVpUnkteXdOcU4xRDNKZ2NOQ2xEWU51bzZVUHFmcmYzcjA3VUd0MUVtRjVZamlsMll2dnJvdlZYVVlmTlZxNjhBZWdJY2VpbVNBT1NlTGI0cVRFMmZGVmpxTWpVU2N3cWs5aHA3d0NUSEVhcW5SbXFkOFFRay1qeEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint's brain surgery drill gets FDA clearance, first clinical use", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZTA1RXktMTJCRnIxLWp5ZlRXTUFXdUJqbTNsZFdDN2VSQnJLSV8xOG4zc0pjZXBXOFU3WGl2UWd2X1VHbGdxcUw0cVA4MmN6SjhDNEQxREh6RmZ3MmxTbWVQeHpLY19aaXRrbGwtN0FXRWloUjB2RlBDcW8zaTJqTkxVNFR3NmdncVN3aVFTRXVhVWNqbEwwTDJoak52bDV2cExvblpZM2QtMEduZXpiWFpUelBOTFRHUi1lTU1qd28?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canada clears ClearPoint brain navigation system for clinical trial sites", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcExGeWt6cHpDVVJPUVQ4VWFVNXNnRnVwZFVQRkVtWDhFTnZRUHc5a2NsQU9zSzQ2Z3pRQzFqOVVReXI4V0NTc0ctVlBVR2lsaWNWbjRQcExGSXEwcW56WXdZU1RNREp3ZmRlaVhBaGRxVktBT1hkcEpTc25HQW1BUXcxaXEzWkdHSWpHcEVLeGZua3RDblRLZUoxMEVIUnBGSHpudmdQUElXclJLWFFMNmFHTzhNQ3podVB3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The ClearPoint Neuro (CLPT) Investment Story Is Shifting On Regulatory And Partnership Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNENYcTJrWkFrbzQzU0lkWnFFWDc0alpsSkxnSlBqQkY3M0pIVVg2RWVSaDAwTm9fdUpTam9UWUdLNEZjTmdMWTd4N1QxX29hcUlrdGdkV1IzUUVzamVaOUNnRTdZWDFGb3JjbjAtRUppblRqenBJSk9GYko4dFhyOGl5NlcxX1pXbzNKV2JSelU0aVRmQU12MncxSVEzUFBPX0RvMVVoTFM?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The ClearPoint Neuro (CLPT) Story Is Shifting After New Partner And FDA Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPVjRmX1l0UFFUV011QmVqb0FHNmZ3cmF2ZWkyNFBYOWdCQTV5TVhWZ1RWMFVOU2Z6T2dRN0k0Uk5NcTEwdE91MzdGOUNva0xIUmxxc05Xc3BmcFYxU1Vma3hfQ0JrSC1xM29QNEFBaU5pVGY1NFV0ZmNxc0E1bEdTdUszWlU0RTk1dnJEa21SeUlwSU1PbjJ1MnE4OGJPcXBCUmc?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearPoint Neuro FY 2025 Revenue Growth Reinforces Bullish Narratives Despite Persistent EPS Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 106, "total_relevant": 75, "sentiment_summary": {"positive": 15, "negative": 9, "neutral": 51, "score": 52, "total": 75, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 24.9, "count": 44}, {"event": "earnings", "label": "Earnings", "weight": 11.69, "count": 24}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 17.5, "latest_week": "2026-07-10", "one_week_move": -6.5, "four_week_move": 30.2, "twelve_week_move": 48.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.503935, "market_dynamics_buy_signal": false, "relative_strength": 6.161533, "fair_value_gap": 58.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.3827, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.5% over one week, +30.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 11}, {"label": "TradingView", "count": 7}, {"label": "Moomoo", "count": 4}, {"label": "Seeking Alpha", "count": 2}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Investing.com Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 64}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 44}, {"label": "Earnings", "count": 24}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "64", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.5% over one week, +30.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "EpilepsyGTx Taps ClearPoint Neuro for EPY201 Clinical Trial Delivery"}], "updated_at": "2026-07-17T06:44:30.632220+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}